1. 2 global travel – who goes? 3 global links of ndm to the uk kumarasamy et al., lancet infect...

11
1

Upload: brenton-crusenberry

Post on 15-Dec-2015

213 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

1

Page 2: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

2

Global Travel – who goes?

Page 3: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

3

Global Links of NDM to the UK

Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

Page 4: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

4

15 million Visitors to the UK 2011Country Rank (by

number)Visitors (000)

USA 1 2,484

Italy 7 1,526India 16 350Brazil 19 276

Greece 25 225Israel 31 164China 33 149Nigeria 34 142Pakistan 48 65

Page 5: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

0

2,000

4,000

6,000

8,000

10,000

12,000

14,000

2005 2006 2007 2008 2009 2010 2011

Year

Vis

ito

rs (

000)

Holiday

VFR

Business

Other

Visitors to the UK by Purpose – potential for MDR GN household spread

Page 6: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

Patient Number Patient No’s

Total completed NHS admission episodes in England 2011*

14,890,844

Total admissions UCLH** 127,364

Total overseas** 1631

Total transferred from another NHS provider**

19

Total transferred from a private provider**

8

Total overseas patients transferred from private provider**

0

Total projected overseas patient admissions 190,751

*HES Data** P. Wilson Pers Comm

Potential Impact of Overseas Patients

Page 7: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

7

Carbapenemase-producing Enterobacteriaceae

in the UK (n = 1659)

Neil Woodford: AMRHAI, Unpublished data

Early cases often imported

Imported & ‘home grown’

Page 8: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

Currently very limited knowledge on basic epidemiology.

CRO carriage rates in specific high risk groups allowing targeted screening?

Duration of carriage? Optimal method of patient screening – rectal

swabs – reliability of self swabbing? Optimal laboratory screening method? Transmission rates in home/hospital? Efficacy of decolonisation and isolation? Cost effectiveness of interventions?

Page 9: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

9

PoliticalCommitment & Investment

Aggressive Infection ..Control• Screening• Isolation• Reinforced Hand ..Hygiene• Contact precautions

SurveillanceTargeted & Structured

Concerted Action Required: ALL Sectors

Focussed Clinical Research

Cross CuttingAntibiotic Policy

AntimicrobialStewardship

Simpler cheaper

laboratory tests

Centralised Reporting

•incl private sector

Unified Strategic Policy in DH/NHS

RenewedDrug Pipeline

Improved GlobalIntelligence

Page 10: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

10

What is the key priority ?

Refocus NHS Infection Prevention and Control onto MDR GNB

Page 11: 1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis 2010 10:597-602

11

Serious threat to routine care in the NHS